Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1263-1272

  Klein, Robert ^a   Wielage, Ron ^a   Muehlenbein, Catherine ^b   Liepa, Astra M ^b   Babineaux, Steve ^b   Lawson, Anthony ^b   Schwartzberg, Lee ^c  

^a Medical Decision Modeling Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c West Clinic   (United States)

Author keywords

Advanced NSCLC; Cost effectiveness; Maintenance therapy; Pemetrexed

Indexed keywords

BEVACIZUMAB; ERLOTINIB; PEMETREXED;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG COST; HISTOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 77955097091     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e15d16     Document Type: Article

References (28)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. V. 2.2008. Available at: . Accessed September 24, 2009.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
3. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):277S-289S. (Pubitemid 47502813)
4. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009;14:137-147.
5. Hensing TA, Schell MJ, Lee JH, et al. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer 2005;47:253-259.
6. Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-464.
7. Prior C, Oroszy S, Oberaigner W, et al. Advanced non-small-cell lung cancer: adjunctive interferon gamma in induction and maintenance therapy. J Cancer Res Clin Oncol 1999;125:42-46.
8. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
9. Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005;23(16 Suppl):7143.
10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
11. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and pac- litaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
12. Brodowicz T, Krzakowshi M, Zwitter M, et al. Cisplatin and gemcitab- ine first-line chemotherapy followed by maintenance gemcitabine or bestsupportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
14. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
15. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open- label randomised phase III trial. Lancet 2009;373:1525-1531.
16. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcit- abine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
17. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC (Abstract). J Clin Oncol 2009; 27(15 Suppl):8001.
18. OSI Pharmaceuticals, Inc. Correcting and replacing data from the phase III SATURN study show Tarceva improved progression-free survival when used as a first-line maintenance therapy for advanced non-small cell lung cancer. Available at: 2009/05/14/businesswire124592352-print.html. Accessed May 17, 2009.
19. Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, August 1, 2009 (Abstract A2.1).
20. Brugger W, Kim JH, Hansen O, et al. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC. 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, August 2, 2009 (Abstract B9.1).
21. Eli Lilly and Company. Alimta package insert. 2008. Available at: . Accessed September 24, 2009.
22. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
23. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263.
24. Grusenmeyer PA, Gralla RJ. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non- small cell lung cancer (Abstract). J Clin Oncol 2006;24(18 Suppl):6057.
25. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) (Abstract). J Clin Oncol 2009;27(18 Suppl):LBA8002.
26. Centers for Medicare & Medicaid Services (CMS). Payment allowance limits for Medicare Part B drugs effective January 1, 2008, through March 31, 2008. Available at: Price/01a-2008aspfiles.asp#TopOfPage. Accessed September 24, 2009.
27. Carlson J, Oestreicher N, Lubeck DP, et al. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 Suppl): Abstract 7664.
28. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.